ReviewCurrent rheumatology reports2014
Economics of non-adherence to biologic therapies in rheumatoid arthritis.
Review in Current rheumatology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review.Journal of managed care & specialty pharmacy · 2023Pooled it
- EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.Annals of the rheumatic diseases · 2022Guideline
- Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count.Rheumatology (Oxford, England) · 2021Trial
- RAPID3 disease activity trajectory among patients with rheumatoid arthritis new to specialty pharmacy medications.Journal of managed care & specialty pharmacy · 2026Article
- Cost-Related Medication Behaviors for Patients With and Without Systemic Autoimmune Rheumatic Diseases.Arthritis care & research · 2025Article
- Prevalence and Factors Associated with De-escalation of Anti-TNFs in Older Adults with Rheumatoid Arthritis: A Medicare Claims-Based Observational Study.Drugs & aging · 2024Observational
- Collating the voice of people with autoimmune diseases: Methodology for the Third Phase of the COVAD Studies.Rheumatology international · 2024Article
- Prevalence and Predictors of Remission and Sustained Remission in Patients with Rheumatoid Arthritis from the United Arab Emirates: A Two-Year Prospective Study.Open access rheumatology : research and reviews · 2023Article
- Usage and Adherence of Seven Advanced Therapies with Differing Mechanisms of Action for Inflammatory Arthritis in Canada.Rheumatology and therapy · 2022Article
- Predictors of not Achieving Remission or Low Disease Activity in Axial Spondyloarthritis Patients from Middle Eastern Countries: A Prospective, Multicenter, Real-world Study.Oman medical journal · 2022Article
- Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis.Journal of clinical medicine · 2022Review
- Understanding multidisciplinary care for people with rheumatic disease in British Columbia, Canada, through patients, nurses and physicians voices: a qualitative policy evaluation.BMC health services research · 2021Article
- Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy.Journal of managed care & specialty pharmacy · 2021Article
- Efficacy and Safety of Metformin Use in Rheumatoid Arthritis: A Randomized Controlled Study.Frontiers in pharmacology · 2021Article
- Patient-provider communication about medication cost in rheumatoid arthritis.Clinical rheumatology · 2021Article
- Integrating E-Prescribing and Pharmacy Claims Data for Predictive Modeling: Comparing Costs and Utilization of Health Plan Members Who Fill Their Initial Medications with Those Who Do Not.Journal of managed care & specialty pharmacy · 2020Article
- Qualitative assessment of medication adherence in patients with rheumatic diseases on biologic therapy.Clinical rheumatology · 2019Article
- Effective factors in non-compliance with therapeutic orders of specialists in outpatient clinics in Iran: a qualitative study.BMC health services research · 2019Article
- Adherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study.Journal of managed care & specialty pharmacy · 2019Article
- Effect of patient education on medication adherence of patients with rheumatoid arthritis: a randomized controlled trial.Patient preference and adherence · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adherence to biologic therapies among patients with rheumatoid arthritis is sub-optimal, with the proportion of adherent patients reported to be as low as 11 %. We found few studies evaluating economic outcomes, including health care costs, associated with non-adherence with biologic therapies. Findings suggest that while higher pharmacy costs drive total health care costs among adherent patients, non-adherent patients incur greater health care utilization including inpatient, outpatient, and laboratory services. Finally, economic factors are important determinants of adherence to biologics in patients with rheumatoid arthritis. Evidence to date has shown that higher out-of-pocket payments have a negative association with adherence to biologics. Furthermore, cost-related non-adherence is a highly prevalent problem in rheumatoid arthritis. Given the high costs of biologics and continued expansion of use in rheumatoid arthritis, there is need for more research to understand the economic implications of adherence to these therapies.
Indexed as
Identifiers
25227187What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.